DDInter1133 DDInter1676
A vesicant and necrotizing irritant destructive to mucous membranes, mechlorethamine is an alkylating drug. It was formerly used as a war gas. The hydrochloride is used as an antineoplastic in Hodgkin's disease and lymphomas. It causes severe gastrointestinal and bone marrow damage. The FDA granted marketing approval for the orphan drug Valchlor (mechlorethamine) gel on August 23, 2013 for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma (CTCL) in patients who have received prior skin-directed therapy. Each tube of Valchlor contains 0.016% of mechlorethamine which is equivalent to 0.02% mechlorethamine HCl.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Mechlorethamine {u} (Compound) resembles {v} (Compound) Cyclophosphamide
Mechlorethamine {u} (Compound) treats {v} (Disease) hematologic cancer
Mechlorethamine {u} (Compound) is included by {v} (Pharmacologic Class) Alkylating Activity
Mechlorethamine {u} (Compound) causes {v} (Side Effect) Thrombosis
Mechlorethamine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Delafloxacin
Mechlorethamine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Warfarin
Mechlorethamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Daunorubicin
Mechlorethamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ustekinumab
Mechlorethamine {u} may lead to a major life threatening interaction when taken with {v} Clozapine
Mechlorethamine {u} may lead to a major life threatening interaction when taken with {v} Leflunomide
Mechlorethamine (Compound) resembles Cyclophosphamide (Compound)
Mechlorethamine (Compound) treats hematologic cancer (Disease)
Mechlorethamine (Compound) is included by Alkylating Activity (Pharmacologic Class)
Mechlorethamine (Compound) causes Thrombosis (Side Effect)
Mechlorethamine may cause a minor interaction that can limit clinical effects when taken with Delafloxacin
Mechlorethamine may cause a minor interaction that can limit clinical effects when taken with Warfarin
Mechlorethamine may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin
Mechlorethamine may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Mechlorethamine may lead to a major life threatening interaction when taken with Clozapine
Mechlorethamine may lead to a major life threatening interaction when taken with Leflunomide